MediciNova, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MNOV Nasdaq 2836 medicinova.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MediciNova, Inc.

2026 New Year’s Greetings from the CEO - Jan 6th, 2026 7:00 am
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy - Dec 18th, 2025 4:00 am
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Dec 9th, 2025 3:31 pm
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - Dec 8th, 2025 4:00 am
Message from the CEO to MediciNova Shareholders - Dec 1st, 2025 4:00 pm
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - Nov 18th, 2025 4:00 am
MediciNova: Q3 Earnings Snapshot - Nov 12th, 2025 3:22 pm
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - Nov 6th, 2025 4:00 pm
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - Nov 4th, 2025 5:00 am
3 Penny Stocks With Market Caps Over $80M To Consider - Nov 3rd, 2025 5:05 am
MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis - Oct 31st, 2025 6:55 pm
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication - Oct 30th, 2025 5:00 pm
MediciNova to Present at the LD Micro Main Event XIX Investor Conference - Oct 6th, 2025 6:00 am
MediciNova concludes subject enrolment in trial of MN-166 - Sep 23rd, 2025 5:13 am
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) - Sep 22nd, 2025 6:00 am
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND - Sep 16th, 2025 6:00 am
MediciNova Provides Shareholder Update on Key Developments - Sep 8th, 2025 7:00 am
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 5:00 am
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial - Aug 26th, 2025 5:00 pm
MediciNova: Q2 Earnings Snapshot - Aug 14th, 2025 3:30 pm